Commit Biologics To Present At Complement Conf

By Author: Ben Gross
Total Articles: 444
Comment this article

Commit Biologics, a company at the forefront of utilizing the complement system to combat cancer and autoimmune diseases, has exciting news to share. They will be presenting a poster at the 16th International Conference on Complement Therapeutics in Greece. The poster will showcase key data on Commit's innovative Bispecific Complement Engaging (BiCE™) platform.

Dr. Nick S. Laursen, Chief Scientific Officer and Co-Founder of Commit Biologics, will be the presenter. The poster's title is "BiCE™ – An antibody platform to enhance complement activation for the treatment of cancer and autoimmune diseases."

The data presented will demonstrate the optimization of the BiCE™ platform and highlight how Commit's second-generation BiCE™ molecules outperform other technologies in terms of complement-mediated cell killing. This groundbreaking technology has a unique mechanism of action, making it a potential leader in the development of therapeutics for cancer and autoimmune diseases.

The complement system, an integral part of the body's immune system, has remained largely untapped for therapeutic purposes until ...
... now. Commit Biologics has developed the BiCE™ platform, which utilizes bispecific single domain antibodies. One arm of these antibodies recognizes the complement protein C1q, while the other arm targets specific cancer antigens or cells driving autoimmune diseases. This innovative approach efficiently recruits C1, resulting in powerful complement activation.

Commit Biologics' poster presentation at the conference will shed light on the immense potential of their BiCE™ platform and its ability to revolutionize the treatment of cancer and autoimmune diseases.

More Information : https://www.techdogs.com/tech-news/pr-newswire/commit-biologics-to-present-data-on-its-bispecific-complement-engaging-bice-platform-at-the-16th-international-conference-on-complement-therapeutics